By integrating genomic data, measurable residual disease (MRD) information, and clinical outcomes, we assessed the impact of KDM6A variants on the cumulative incidence of relapse in 1676 adults with AML in histological remission, including a subgroup of 207 patients with RUNX1::RUNX1T1 fusion. This evidence concerns the gene RUNX1 and acute myeloid leukemia.